DrugDex Endorsed As Off-Label Chemotherapy Guide For Medicare Coverage
CMS now recognizes Thomson Micromedex's DrugDex compendium as an authoritative reference for determining off-label coverage of cancer drugs under Medicare Part B, the agency announced June 10